Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Jiangsu Hengrui Medicine Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is handled by 1 distinct examiner working in 1 distinct art unit. This reflects a specialized focus in the company's current patenting efforts with no diversification across different administrative divisions.
The busiest examiner for this portfolio is SKOKO III, JOHN JOSEPH, who is responsible for 1 busiest examiner pending office action. Because there is only 1 distinct examiner for the entire portfolio, SKOKO III, JOHN JOSEPH is managing all of the company's current pending actions. This concentration means that the company's immediate patent outcomes are tied to the specific interpretations of this individual.
The presence of 1 distinct art unit confirms that the technical subject matter is being reviewed within a single specialized group. With 1 pending office action in total, the portfolio's current activity is centralized. Practitioners can focus their strategy on the requirements of the 1 distinct examiner to resolve the company's current pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.1% | +58.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794732 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | SKOKO III, JOHN JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794732 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | SKOKO III, JOHN JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17794732 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | SKOKO III, JOHN JOSEPH | 1643 | §103§112Other | Non-Final OA | — | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial